Loading Events

Dr Carolyn Owen from the Tom Baker Cancer Centre in Calgary will be the speaker at our upcoming National Zoom meeting.  Her topic is “After Bendamustine and Rituxan … then what?”.

Dr. Owen is Professor in the Division of Hematology & Hematological Malignancies, University of Calgary, and Hematologist at the Tom Baker Cancer Centre.  She is also the Lead Investigator at the Tom Baker Cancer Centre for the clinical trial of Nemtabrutinib, which we have reported on.

As the title says, she will be talking about what follows the standard first-line treatment in Canada, which is, typically, Bendamustine+Rituximab.  But for a growing number of WMers in Canada, this includes the very important question, what follows a BTK inhibitor?   The answer might well be the kind of drug in her clinical trial, because Nemtabrutinib is another member of the new class of non-covalent BTK inhibitors.

And, to top it all off, there will be an opportunity for Q&A!

Zoom information:

Go to Top